{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-035788","form_type":"8-K/A","ticker":"ZVSA","cik":"0001859007","company_name":"ZyVersa Therapeutics, Inc.","filed_at":"2022-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.807209+00:00","generated_at":"2026-06-21T03:40:51.884755+00:00","sec_items":["2.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ZyVersa reports Q3 2022 net loss of $3.7M, R&D spend up 473% YoY","bullets":["Net loss of $3.693M for Q3 2022 vs $1.879M in Q3 2021; nine-month loss $9.445M.","R&D expenses surged to $2.334M in Q3 2022 from $0.407M, driven by $1.928M in IC100 drug manufacturing.","Cash used in operations improved to $1.078M for nine months 2022 from $4.460M in 2021.","Financing provided $1.353M via preferred stock private placement; no revenue disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-035788","json":"https://secwatch.observer/filing/0001493152-22-035788.json","markdown":"https://secwatch.observer/filing/0001493152-22-035788.md","text":"https://secwatch.observer/filing/0001493152-22-035788.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035788/0001493152-22-035788-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035788/form8-ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T03:40:51.884755+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}